This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Take the CME quiz:
 Vol. 16 No. 1, July 2006
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Varma, S. K.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Varma, S. K.

AAP Grand Rounds 16:81-82 (2006)
© 2006 American Academy of Pediatrics

ADOLESCENT MEDICINE

Adolescent Polycystic Ovary Syndrome: Randomized Study of Metformin

Source: Bridger T, MacDonald S, Baltzer F, et al. Randomized placebo-controlled trial of metformin for adolescents with polycystic ovary syndrome. Arch Pediatr Adolesc Med. 2006;160:241–246; doi:10.1001/archpedi.160.3.241[Abstract/Free Full Text]

The first 20% of the full text of this article appears below.

Polycystic ovary syndrome (PCOS) is a common disorder among women, diagnosed in at least 5% to 10% of women between adolescence and menopause. Symptoms include menstrual dysfunction and hyperandrogenism. Insulin resistance and hyperinsulinemia may play a role in PCOS by promoting excess androgen production, and insulin sensitizing agents like metformin have resulted in improved clinical status in some adult women. Investigators from the University of Newfoundland in St. Johns and McGill University in Montreal performed a randomized, placebo-controlled, double-blind trial using metformin for PCOS in adolescents. A total of 22 adolescents with hyperinsulinemia and PCOS were enrolled from the ambulatory endocrinology adolescent clinic at Montreal Children’s Hospital between 1999 and 2002. Participants were between 13 and 18 years of age with menarche at least . . . [Full Text of this Article]

Surendra K. Varma, MD, FAAP
Texas Tech University Health Sciences Center, Lubbock, TX